With a slim House majority, will Republicans wade into Medicare coverage policy for a promising Alzheimer’s drug and the new Medicare price negotiation program? Democratic Senate could offer ‘counter oversight’ hearings.
Congressional Republicans may need to “scramble” to help ensure meaningful Medicare coverage for Eisai Co., Ltd./Biogen, Inc.’s lecanemab if it is approved by the US Food and Drug Administration for Alzheimer's disease next year, according to health policy expert Jennifer Young.
Young who is a partner at the health care policy consultancy Tarplin, Downs and Young, discussed House Republican’s health care...
The Council of the EU has made several key amendments to the legislative reform package, which it will now negotiate with the European Parliament.
Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.
The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.
